Fig. 2From: ALDH2 polymorphism rs671 is a predictor of PD-1/PD-L1 inhibitor efficacy against thoracic malignanciesProgression-free survival after the initiation of immune checkpoint inhibitor therapy by ALDH2 rs671 polymorphism. Kaplan–Meier plots were shown for patients with thoracic malignancies. ICI; immune checkpoint inhibitor, Rs671(−); ALDH2*1/*1, rs671(+); ALDH2*1/*2 or ALDH2*2/*2. p, p value for Gahan–Breslow–Wilcoxon testBack to article page